sarcoma | GenomeWeb

sarcoma

An epigenetic analysis showed that the tumors all shared a certain DNA methylation signature, but that methylation patterns varied between samples.

The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.

Rare germline mutations in cancer risk genes turned up in more than half of sarcoma patients tested by gene panel sequencing.

The UPenn-led study proposal calls for editing three genes in autologous T cells with CRISPR and includes preliminary data for on- and off-target editing.

An analysis of angiosarcoma-derived cell lines identified a NUP160-SLC43A3 fusion that subsequently turned up in aggressive primary tumor samples.

A five-gene signature was linked to both event-free survival and overall survival in individuals with a type of rhabdomyosarcoma missing a prognostically informative gene fusion.

The group is currently comparing a lab-developed nCounter assay to "gold-standard" RT-PCR assays to retrospectively analyze sarcoma patient samples.

MGH runs the clinical fusion assay for all lung cancer patients and the Snapshot NGS test on all patients with solid tumors. It is planning to expand the assays and is also developing a fusion panel for hematological malignancies.

NEW YORK (GenomeWeb News) – The Sarcoma Alliance for Research through Collaboration, or SARC, today announced it has received a five-year, $11.5 million grant from the National Cancer Institute to conduct translational research into sarcoma, a relatively rare cancer than can affect bones and soft

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.